Amgen's Q4 earnings call reveals a challenging year ahead. The company faces ESA franchise declines, competitive pressures and regulatory uncertainties. However, the pipeline holds promise, with positive Denosumab trial results and advancements in other areas offering potential long-term growth. Short-term challenges will impact 2008 revenues and earnings, leading to a cautious stock performance in the coming weeks. [-1]